Potential utility of gonadotropin-releasing hormone agonists in the management of ovarian hyperandrogenism.
Gonadotropin-releasing hormone agonists are potent suppressors of ovarian androgen biosynthesis even in the face of severe hyperandrogenism (e.g., hyperinsulinemia, hyperthecosis). Gonadotropin-releasing hormone agonists are clinically useful in the context of hirsutism. The use of Gn-RH-a in the context of hirsutism is not duration-limited in that the induced hypoestrogenism and its consequent complications are likely to be effectively managed by the concurrent provision of estrogen replacement therapy.
Adashi
E Y
EY
Department of Obstetrics and Gynecology, University of Maryland School of Medicine, Baltimore.
D000726:Androgen Antagonists / Q000627:therapeutic use; D000728:Androgens / Q000378:metabolism*; D001696:Biomechanical Phenomena; D003276:Contraceptives, Oral / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D004967:Estrogens / Q000627:therapeutic use; D005260:Female; D006628:Hirsutism / Q000503:physiopathology; D006801:Humans; D010049:Ovarian Diseases / Q000188:drug therapy* / Q000378:metabolism / Q000503:physiopathology; D010906:Pituitary Hormone-Releasing Hormones / Q000502:physiology*; D011374:Progesterone / Q000627:therapeutic use; D013148:Spironolactone / Q000627:therapeutic use
D000726:Androgen Antagonists; D000728:Androgens; D003276:Contraceptives, Oral; D004967:Estrogens; D010906:Pituitary Hormone-Releasing Hormones; D013148:Spironolactone; D011374:Progesterone